|
|
Provigil - Newsfeeds
-
-
anxiety), Plavix (blood clot prevention), Provigil (excessive sleepiness), Seroquel (schizophrenia, bipolar disorder), Singulair (asthma, allergy symptoms), TriCor (high cholesterol). Again, according to the report, these common brands could see price ...
-
-
“And maybe do a slightly better job than current owners.” In Cephalon, Valeant would inherit Provigil, a medicine for the sleep disorder narcolepsy that faces generic competition next year. Cephalon has been trying to move patients to a new version ...
-
-
With Provigil sales remaining strong, we remain concerned about the slower-than-expected conversion of patients to Nuvigil. Both 2012 and 2013 should be challenging years for the company due to the genericization of Provigil. We are nevertheless pleased ...
-
-
Cephalon makes sleep disorder drug Provigil and the cancer drug Treanda. It has called Valeant's offer of $73 a share inadequate. Valeant Pharmaceuticals International Inc., based near Toronto, Ontario, sells treatments for chronic illnesses and generic drugs.
-
-
O ). By that logic, Cephalon would seem an unlikely takeover candidate. It faces the U.S. patent expiry in 2012 for its Provigil sleep disorder drug, which amounted to about 40 percent of its revenue last year. But the U.S. drugmaker made an alluring ...
-
-
INDIANAPOLIS (AP) - Former UConn star Diana Taurasi is making a surprise appearance at the Final Four. Taurasi flew from her home in Phoenix to Indianapolis late Saturday to be on hand to watch her beloved Huskies play Notre Dame in the national semifinals ...
-
-
Now, it will be in the stockholders’ hands.” Cephalon reported 2010 revenue of $2.81 billion. The company sells the narcolepsy treatment Provigil, which last year generated sales of $1.12 billion. The medicine faces a loss of patent protection in April 2012.
-
-
anxiety), Plavix (blood clot prevention), Provigil (excessive sleepiness), Seroquel (schizophrenia, bipolar disorder), Singulair (asthma, allergy symptoms), TriCor (high cholesterol). Again, according to the report, these common brands could see price ...
-
-
The Valeant offer comes at a time when Cephalon is preparing for the loss of patent protection for its top-selling drug Provigil,a treatment for narcolepsy and other sleep-associated disorders. In rejecting the Valeant offer, Cephalon’s board said ...
-
-
Cephalon makes sleep disorder drug Provigil and the cancer drug Treanda,. Valeant, Mississauga, Ontario, sells treatments for chronic illnesses and generic drugs. Its product portfolio includes Acanya Gel for acne and the migraine treatment Migranal.
-
-
Cephalon, which makes sleep disorder drug Provigil and the cancer drug Treanda, has called Valeant's offer of $73 a share inadequate.
-
-
With Provigil sales remaining strong, we remain concerned about the slower-than-expected conversion of patients to Nuvigil. Both 2012 and 2013 should be challenging years for the company due to the genericization of Provigil. We are nevertheless pleased ...
-
-
O ). By that logic, Cephalon would seem an unlikely takeover candidate. It faces the U.S. patent expiry in 2012 for its Provigil sleep disorder drug, which amounted to about 40 percent of its revenue last year. But the U.S. drugmaker made an alluring ...
-
-
Now, it will be in the stockholders’ hands.” Cephalon reported 2010 revenue of $2.81 billion. The company sells the narcolepsy treatment Provigil, which last year generated sales of $1.12 billion. The medicine faces a loss of patent protection in April 2012.
-
-
She had been provisionally suspended by the Turkish Basketball Federation after two samples tested positive for modafinil, but the lab that performed the test retracted its report two months later. Taurasi has been looking forward to focusing on basketball ...
-
-
“So we will go to shareholders. If they don’t like it, we will walk in a month.” Provigil, Treanda Cephalon reported 2010 revenue of $2.81 billion. The company sells the narcolepsy treatment Provigil, which last year generated sales of $1.12 ...
-
-
HARD TO VALUE Analysts are divided over the value of Cephalon, which faces the loss of U.S. exclusivity for its top-selling Provigil sleep-disorder drug next year. Continued...
-
-
Cephalon fell on concern its experimental medicines wouldn’t make up for the loss of revenue after its top-selling Provigil drug loses patent protection in 2012, Timothy Chiang, an analyst at CRT Capital Group LLC in Stamford , Connecticut , said in a ...
-
-
Cephalon fell on concern its experimental medicines wouldn’t make up for the loss of revenue after its top-selling Provigil drug loses patent protection in 2012, Timothy Chiang, an analyst at CRT Capital Group LLC in Stamford, Connecticut, said in a ...
-
-
anxiety), Plavix (blood clot prevention), Provigil (excessive sleepiness), Seroquel (schizophrenia, bipolar disorder), Singulair (asthma, allergy symptoms), TriCor (high cholesterol). Again, according to the report, these common brands could see price ...
Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.
Pages:
Previous
1
2
3
4
5
6
7
8
9
10
11
...
Next
|
|
